Flea Allergy Inhibitor Compositions Using T Regulatory Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective pharmacotherapeutic and preventive measures for flea allergy dermatitis, a common skin condition in cats and dogs caused by allergic reactions to flea saliva, leading to severe skin irritation and potential infections.
Innovation Solution
Compositions and kits comprising eukaryotic cell expression vectors encoding flea allergenic protein sequences and corresponding proteins or peptides, administered to induce antigen-specific T regulatory cells to suppress allergic responses, thereby preventing and inhibiting flea allergy dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If nonspecific immunosuppressive drugs or monoclonal antibodies are used to treat allergic reactions, then allergic responses are suppressed, but the ability to fight infections is compromised
Solution Approach 1:
The patent applies local quality by targeting the immune response specifically at the site of allergen exposure through localized immunization. The composition delivers allergen-specific T regulatory cells and antibodies locally, suppressing allergic reactions only where needed without affecting system-wide infection defense mechanisms.
Solution Approach 2:
The patent uses an intermediary approach by introducing T regulatory cells as mediators between the allergen and the immune system. These regulatory cells act as intermediaries that selectively suppress allergic responses while preserving normal immune function, thereby resolving the contradiction between allergy control and infection resistance.
2Object-affected harmful factors
If redirecting immunity from Th2 type to Th1 type is attempted, then allergic responses are modulated, but success is limited
Solution Approach 1:
The patent applies copying by creating a simplified model of the immune response using recombinant DNA technology. The expression vector contains a simplified version of the allergen gene that produces T regulatory cells with specific anti-allergic properties, effectively copying and amplifying the desired immune response without the complexity of natural infection-based redirection.
Solution Approach 2:
The patent changes the parameter of immune cell differentiation by using molecular cues in the expression vector to guide T cell development toward a regulatory phenotype. This parameter change enables reliable redirection of immunity by controlling the differentiation pathways of naive T cells during immunization.
3Ease of operation
If no effective pharmacotherapeutic or preventive methods exist for flea allergy dermatitis, then the condition remains untreated, but severe skin irritation and infections occur
Solution Approach 1:
The patent applies preliminary action by providing preventive immunization before flea allergy dermatitis develops. The composition is administered in advance to induce protective T regulatory cells and antibodies, preventing the allergic reaction before it occurs rather than treating symptoms after they manifest.
Solution Approach 2:
The patent converts the harmful flea allergen into a beneficial tool for immunization. By using the allergen itself as the immunizing agent within a controlled expression vector system, the composition transforms the harmful substance into a protective stimulus that induces specific T regulatory cells and antibodies against future allergic reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively reduces allergic reactions by inducing antigen-specific immunosuppression, inhibiting IgE production, and suppressing CD4+ T cell proliferation, providing a therapeutic and preventive approach to flea allergy dermatitis.
Implementation Method 1
a eukaryotic cell expression vector comprising a nucleotide sequences encoding the amino acid sequence of SEQ ID NOs:2 or 23
Implementation Method 2
inducing antigen-specific T regulatory cells to suppress allergic responses, thereby preventing and inhibiting flea allergy dermatitis
Implementation Method 3
inhibiting IgE production
Implementation Method 4
suppressing CD4+ T cell proliferation
Data Source
Figure 1a~1c
Figure 2a
Figure 2b
AI summary
Compositions and kits for inhibiting an allergic response against an allergenic protein are disclosed. The compositions comprise a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein; and an allergenic protein or a polypeptide that comprises an antigenic epitope of the allergenic protein. The kits comprise a first container which comprises a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of the allergenic protein and a second container which comprises an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein. Compositions and kits for inhibiting an allergic response against an flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed. Methods if using such compositions and kits are also disclosed.